Apellis Pharmaceuticals (APLS) Expected to Announce Earnings on Tuesday

Apellis Pharmaceuticals (NASDAQ:APLS) is anticipated to release its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect Apellis Pharmaceuticals to post earnings of ($0.41) per share and revenue of $199.2760 million for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 8:30 AM ET.

Apellis Pharmaceuticals Trading Down 2.3%

Shares of APLS opened at $22.28 on Friday. The stock has a market capitalization of $2.82 billion, a P/E ratio of 71.87 and a beta of 0.26. Apellis Pharmaceuticals has a twelve month low of $16.10 and a twelve month high of $30.48. The company has a quick ratio of 3.10, a current ratio of 3.54 and a debt-to-equity ratio of 0.90. The firm has a fifty day simple moving average of $23.31 and a two-hundred day simple moving average of $23.87.

Insider Transactions at Apellis Pharmaceuticals

In other news, insider Nur Nicholson sold 7,725 shares of the firm’s stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $21.77, for a total value of $168,173.25. Following the completion of the transaction, the insider owned 71,118 shares in the company, valued at $1,548,238.86. This trade represents a 9.80% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Cedric Francois sold 27,192 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $21.77, for a total value of $591,969.84. Following the sale, the chief executive officer owned 286,045 shares in the company, valued at $6,227,199.65. This represents a 8.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 120,537 shares of company stock worth $2,608,532. 6.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Osaic Holdings Inc. lifted its position in Apellis Pharmaceuticals by 141.2% during the 2nd quarter. Osaic Holdings Inc. now owns 2,682 shares of the company’s stock valued at $47,000 after acquiring an additional 1,570 shares during the period. Quantbot Technologies LP bought a new position in shares of Apellis Pharmaceuticals during the third quarter valued at approximately $64,000. EverSource Wealth Advisors LLC lifted its holdings in shares of Apellis Pharmaceuticals by 338.5% during the second quarter. EverSource Wealth Advisors LLC now owns 5,429 shares of the company’s stock valued at $94,000 after purchasing an additional 4,191 shares during the last quarter. Headlands Technologies LLC lifted its holdings in shares of Apellis Pharmaceuticals by 748.8% during the second quarter. Headlands Technologies LLC now owns 6,892 shares of the company’s stock valued at $119,000 after purchasing an additional 6,080 shares during the last quarter. Finally, Laurel Oak Wealth Management LLC bought a new stake in shares of Apellis Pharmaceuticals in the 4th quarter worth approximately $213,000. 96.29% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

APLS has been the subject of a number of analyst reports. TD Cowen dropped their target price on shares of Apellis Pharmaceuticals from $50.00 to $45.00 and set a “buy” rating for the company in a report on Friday, October 31st. JPMorgan Chase & Co. dropped their price objective on Apellis Pharmaceuticals from $40.00 to $36.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. Wall Street Zen upgraded Apellis Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Citigroup decreased their target price on Apellis Pharmaceuticals from $52.00 to $45.00 and set a “buy” rating for the company in a report on Friday, October 31st. Finally, Cantor Fitzgerald dropped their price target on Apellis Pharmaceuticals from $39.00 to $35.00 and set an “overweight” rating for the company in a research note on Tuesday, January 13th. Twelve analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $33.00.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.